Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Tapolca – page 16

245 clinical trials in Tapolca, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Tapolca at a glance
245
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

245 trials in Tapolca

Open in trial search

Obesity+1

Not recruiting

Study on Maridebart Cafraglutide for Adults with Type 2 Diabetes and Obesity or Overweight

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Study Comparing EYP-1901 and Aflibercept for Patients with Wet Age-Related Macular Degeneration

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyepoint Inc.

Type 2 diabetes mellitus+1

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Patients with Type 2 Diabetes and Obesity

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim Espana S.A.

Pain+1

Not recruiting

Comparison of bovine and marine chondroitin sulfate tablets (800 mg) in treating knee osteoarthritis pain and functional impairment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Chondroitin sulfate (marine)
  • Sponsor:IBSA Institut Biochimique SA

Obesity+1

Not recruiting

Study on the Effects of PF-07976016 and Liraglutide in Adults with Obesity

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Liraglutide
  • Sponsor:Pfizer Inc.

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Study on Sotagliflozin for Improving Symptoms in Patients with Hypertrophic Cardiomyopathy

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Sotagliflozin
  • Sponsor:Lexicon Pharmaceuticals Inc.

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Dermatitis atopic

Not recruiting

Study on the Effectiveness of Ruxolitinib Cream for Adults with Moderate Atopic Dermatitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Opthea Limited

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Astrazeneca AB

Hypertriglyceridaemia

Not recruiting

Study on Plozasiran and ARO-APOC3 for Adults with Severe Hypertriglyceridemia

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Tapolca

What the registry says about research in the country

01 Respiratory Medicine

Innovative clinical research focusing on Chronic Obstructive Pulmonary Disease (COPD) management through advanced combination therapy approaches. The studies aim to evaluate new treatment options for improving cardiopulmonary outcomes in patients.

  • Triple Therapy Evaluation
  • Cardiopulmonary Outcomes
  • Bronchodilator Treatment

The research examines the comparative effectiveness of combination therapies including budesonide, glycopyrronium, and formoterol in treating COPD, with special attention to severe cardiopulmonary manifestations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.